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Abstract
Objective: We evaluated the impact of chronic kidney disease (CKD) on the presence and severity of aortic
stenosis (AS) in patients at high risk for coronary artery disease (CAD).
Methods: One hundred and twenty consecutive patients who underwent invasive coronary angiography were
enrolled. Aortic valve area (AVA) was calculated by the continuity equation using transthoracic echocardiography,
and was normalized by body surface area (AVA index).
Results: Among all 120 patients, 78% had CAD, 55% had CKD (stage 3: 81%; stage 4: 19%), and 34% had AS (AVA <
2.0cm
2). Patients with AS were older, more often female, and had a higher frequency of CKD than those without AS,
but the prevalence of CAD and most other coexisting conventional risk factors was similar between patients with and
without AS. Multivariate linear regression analysis indicated that only CKD and CAD were independent determinants of
AVA index with standardized coefficients of -0.37 and -0.28, respectively. When patients were divided into 3 groups
(group 1: absence of CKD and CAD, n = 16; group 2: presence of either CKD or CAD, n = 51; and group 3: presence of
both CKD and CAD, n = 53), group 3 had the smallest AVA index (1.19 ± 0.30*# cm
2/m
2, *p < 0.05 vs. group 1: 1.65 ±
0.32 cm
2/m
2, and #p < 0.05 vs. group 2: 1.43 ± 0.29* cm
2/m
2) and the highest peak velocity across the aortic valve
(1.53 ± 0.41*# m/sec; *p < 0.05 vs. group 1: 1.28 ± 0.29 m/sec, and #p < 0.05 vs. group 2: 1.35 ± 0.27 m/sec).
Conclusion: CKD, even pre-stage 5 CKD, has a more powerful impact on the presence and severity of AS than
other conventional risk factors for atherosclerosis in patients at high risk for CAD.
Keywords: Echocardiography, Aortic valve area, Coronary artery disease, Chronic kidney disease
Introduction
Calcific aortic valve disease is associated with increased
cardiovascular risk [1,2]. There are significant similarities
in clinical risk factors and histopathological alterations
between calcific aortic valve disease and coronary athero-
sclerosis [3]. It is also widely recognized that both cardiac
and renal diseases are commonly present in the same
patient, and the presence of chronic kidney disease
(CKD) further accelerates and amplifies the process of
aortic valve calcification via multiple pathways, such as
altered mineral metabolism, inflammation, oxidative
stress, and pressure and volume overload [4,5]. Previous
studies have demonstrated an association between end-
stage renal disease and calcific cardiovascular disease,
especially in patients on dialysis [6-9]; however, less is
known about the impact of early stage CKD on the pre-
valence and severity of calcific aortic valve disease.
Accordingly, we tested the hypo t h e s i st h a tp a t i e n t sw i t h
early stage CKD not yet on dialysis who are at high risk
for coronary atherosclerosis have an increased risk for
developing calcific aortic valve disease.
Patients and Methods
Study Population
We prospectively evaluated the presence and severity of
calcific aortic valve disease in a consecutive series of 146
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September 2009 and March 2010 because of suspected
coronary artery disease or for follow up angiography after
coronary angioplasty or coronary artery bypass graft sur-
gery. We excluded 1 patient with rheumatic heart dis-
ease, 1 patient with severe aortic regurgitation due to
infective endocarditis, 1 patient with a bicuspid aortic
valve, and 8 patients with prosthetic valves due to specific
pathophysiologic conditions that affect the aortic valve
area other than “calcific” aortic stenosis. One patient
with known severe aortic stenosis who was referred to
our hospital for preoperative evaluation, not for the sus-
picion of coronary artery disease, was also excluded. Nine
patients with end-stage renal disease treated with hemo-
dialysis were not included in the present study to exclude
the confounding effect of hemodialysis on the progres-
sion of aortic valve sclerosis. Five patients with severe
mitral regurgitation caused by valve disease were
excluded because the aortic valve area in these patients
can be underestimated due to their low-flow state, even if
the aortic valve is normal. Accordingly, the patient study
group consisted of 120 patients (mean age 67 ± 13 years,
33-91 years, 97 males). CKD was defined as kidney
damage or the presence of an estimated glomerular filtra-
tion rate (eGFR) < 60 ml/min/1.73 m
2 for 3 months or
more, irrespective of cause [10,11]. The eGFR of each
patient was calculated from their serum creatinine (SCr)
value and their age using the following equation [12]:
eGFR (ml/min/1.73 m
2)=1 9 4×A g e
-0.287 ×S C r
-1.094 (if
female × 0.739). Kidney damage was ascertained by the
presence of albuminuria, defined as albumin-to-creatinine
ratio > 30 mg/g in two of three spot urine specimens
[10,11]. CKD was staged according to accepted NIH/
NIDDK Kidney Disease Outcomes Quality Initiative stan-
dards [11]. The protocol was approved for use by the
Human Studies Subcommittee of Mie University Graduate
School of Medicine.
Echocardiography
All patients underwent complete transthoracic echocar-
diography using a Vivid 7 system (GE-Vingmed, Horten,
Norway) and an Aplio Artida ultrasound system (Toshiba
Medical Systems Corp., Tokyo, Japan) within 2 months
before or after coronary angiography. Arm-cuff blood
pressure measurements were performed at the beginning
of each echocardiographic study for all patients. The size
of the aorta and left atrium, interventricular and left ven-
tricular (LV) posterior wall thicknesses, LV end-diastolic
and end-systolic dimensions, and fractional shortening
were assessed from the parasternal long axis view [13].
The LV outflow tract (LVOT) diameter was measured in
the parasternal long-axis view in mid-systole, and then
converted to LVOT area (LVOT area = π × (0.5 × LVOT
diameter)
2) [14,15]. Doppler-derived stroke volume was
calculated as the product of the LVOT area and the
LVOT velocity time integral (VTI) obtained by pulsed
Doppler [15]. The ratio of peak early diastolic transmitral
flow velocity to peak early diastole mitral annular velocity
(E’) at the lateral site in the mitral annulus (E/E’) was cal-
culated as a Doppler parameter reflecting LV filling pres-
sure [16,17]. Aortic valve area (AVA) was calculated by
t h ec o n t i n u i t ye q u a t i o n ;A V A=( L V O Ta r e×L V O T
VTI)/trans-aortic VTI [18,19]. Severity of aortic stenosis
(AS) was defined as follows: severe stenosis, AVA < 1.0
cm
2; moderate stenosis, AVA 1.0 to 1.5 cm
2; and mild ste-
nosis, AVA 1.5 to 2.0 cm
2 [20]. AVA index, normalized by
body surface area, was also calculated [20]. Peak velocity
and mean pressure gradient across the aortic valve were
also measured [20]. Aortic calcification was defined upon
increased thickness and bright echoes of the valve leaflets.
All Doppler values represent an average of 3 beats in the
case of sinus rhythm and an average of 5 beats in the case
of atrial fibrillation.
Coronary Angiography
Coronary artery disease (CAD) was defined as a history of
myocardial infarction, coronaryangioplasty, coronary
artery bypass graft surgery, and a ≥ 50% luminal diameter
stenosis in ≥ 1 epicardial coronary artery by quantitative
coronary angiography. Selective catheter coronary angio-
graphy was performed via the transradial or transbrachial
Judkins approach using standard techniques after nitrogly-
cerin administration. Quantitative coronary angiography
was performed using an automated edge-detection system
(QAngioXA, MEDIS medical imaging systems, Leiden, the
Netherlands) by a single observer unaware of the echocar-
diographic results. At least 2 orthogonal projections were
evaluated, and measurement of percent diameter stenosis
was performed in the projection showing the highest
degree of narrowing.
Statistical Analysis
Continuous variables were presented by mean and stan-
dard deviation and compared using a Student’stt e s to r
the Mann-Whitney’s U test. Bonferroni correction was
applied for multiple comparisons. Categorical variables
were presented as percent frequencies and differences
between proportions were compared using c
2 test. P-




All patients underwent successful coronary angiography
and transthoracic echocardiography. Of 120 patients, 2
patients (2%) had severe AS, 9 patients (8%) had moder-
ate AS, and 30 patients (25%) had mild AS. Table 1
shows the clinical characteristics of the study subjects.
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Page 2 of 9Patients with AS were older, more often female, and had
smaller body sizes than those without AS. The prevalence
of coexisting hypertension, diabetes mellitus, and dyslipi-
demia was similar between the two patient groups, but
patients with AS were less often categorized as current
smokers than those without AS. Ninety-three of all 120
patients (78%) had CAD, and 56% of CAD patients had
multi-vessel disease. The prevalence of CAD was similar
between patients with and without AS. Of all 120
patients, 53% had CKD; 81% of these had stage 3 CKD
( e G F R5 9t o3 0m l / m i n / 1 . 7 3m
2) and 19% had stage 4
CKD (eGFR 29 to 15 ml/min/1.73 m
2). Patients with AS
had a greater occurrence of CKD than those without AS.
Patients with and without AS received similar medica-
tions. Although patients with AS had lower eGFR than
those without AS, serum hemoglobin, calcium, and phos-
phate levels were similar between the two patients
groups. Plasma lipid profile levels, hemoglobin A1C, and
c-reactive protein were not significantly different between
the two patient groups.
Echocardiographic Data
Table 2 shows the echcardiographic data from the study
subjects. LV geometry and fractional shortening were
similar between patients with and without AS. LVOT
diameter and stroke volume were lower in patients with
AS; however, stroke volume index was similar between
patients with and without AS (33 ± 9 and 36 ± 8 ml/m
2,
p = ns). E/E’ was similar between patients with and with-
out AS. Aortic valve calcification was more frequent in
patients with AS compared to those without AS. Peak
velocity and the mean pressure gradient across the aortic
valve during ejection were higher and AVA was smaller
in patients with AS compared to those without AS.
Determinants of AVA Index
Multivariate linear regression analysis was used to iden-
tify clinical (age, gender, blood pressures, presences of
hypertension, diabetes mellitus, dyslipidemia, current
smoking, CAD, CKD, medication uses, and laboratory
measurements) and echocardiographic variables that
might predict AVA index with a stepwise method. The
results indicated that only the presence of CKD and
CAD were independent determinants of AVA index with
standardized coefficients of -0.37 and -0.28, respectively.
Figures 1 and 2 show typical examples of 2-dimentioal
and Doppler echocardiographic appearances of the aortic
valve in a patient without CKD or CAD, and a patient
with both CKD and CAD, respectively. The patient with-
out CKD or CAD (62 year-old male, eGFR: 78 ml/min/
1.73 m
2) had non-calcified aortic valve with calculated
AVA of 3.2 cm
2 (Figure 1). In contrast, the patient with
both CKD and CAD (77 year-old male, eGFR: 48 ml/
min/1.73 m
2, 1 vessel disease) had a restricted aortic
valve with calculated AVA of 1.7 cm
2 and a turbulent
flow across the valve with peak velocity of 2.2 m/sec
(Figure 2). When dividing patients into 3 groups accord-
ing to the presence or absence of CKD and CAD (group
1: absence of CKD and CAD; group 2: presence of either
C K Do rC A D ;g r o u p3 :p r e s e n c eo fb o t hC K Da n d
CAD), group 2 had significantly lower AVA index than
group 1, and group 3 had significantly lower AVA index
than both groups 1 and 2 (group 1: 1.65 ± 0.32 cm
2/m
2;
group 2: 1.43 ± 0.29* cm
2/m
2; and group 3: 1.19 ± 0.30*#
cm
2/m
2; *p < 0.05 vs. group 1, and #p < 0.05 vs. group 2,
respectively; Figure 3). Peak velocity across the aortic
valve was significantly higher in the group 3 than both
g r o u p s1a n d2( g r o u p1 :1 . 2 8±0 . 2 9m / s e c ;g r o u p2 :
1.35 ± 0.27 m/sec; and group 3: 1.53 ± 0.41*#m/sec; *p <
0.05 vs. group 1, and #p < 0.05 vs. group 2, respectively;
Figure 4).
Table 1 Clinical Characteristics of Study Subjects
Non-AS (n = 79) AS (n = 41)
Demographics
Mean age, years 65 ± 12 72 ± 12*
Female gender, % 11 34*
Height, cm 165 ± 8 157 ± 9*
Body weight, kg 65 ± 12 58 ± 10*
Systolic blood pressure, mmHg 129 ± 21 137 ± 28
Heart rate, beats/min 67 ± 12 69 ± 14
Medical history
Hypertension, % 70 78
Diabetes mellitus, % 34 39
Dyslipidemia, % 67 71
Current smoking, % 46 20*
Coronary artery disease, % 73 85
Chronic kidney disease, % 41 76*
Medication use
Beta blocker, % 27 29
Calcium channel blocker, % 39 44
ACEI/ARB, % 56 66
Diuretics, % 20 20
Statin, % 46 46
Measurements
eGFR, ml/min/1.73 m
2 64 ± 23 53 ± 18*
Hemoglobin, g/dl 13.2 ± 2.0 12.8 ± 1.9
Calcium, mg/dl 9.4 ± 0.6 9.5 ± 0.6
Phosphate, mg/dl 3.4 ± 0.6 3.4 ± 0.6
Total cholesterol, mg/dl 185 ± 44 182 ± 30
HDL-cholesterol, mg/dl 50 ± 18 50 ± 14
LDL-cholesterol, mg/dl 108 ± 36 105 ± 24
Triglyceride, mg/dl 135 ± 64 131 ± 55
Hemoglobin A1C, % 6.0 ± 1.0 6.1 ± 0.8
C-reactive protein, mg/dl 0.20 ± 0.28 0.32 ± 0.79
AS: aortic stenosis; ACEI: angiotensin converting enzyme inhibitor; ARB:
angiotensin receptor blocker; eGFR: estimated glomerular filtration rate; HDL:
high density lipoprotein; LDL: low density lipoprotein. *P < 0.05 versus non-AS.
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Non-AS (n = 79) AS (n = 41)
Aortic diameter, mm 30 ± 3 29 ± 2
Left atrial diameter, mm 38 ± 6 39 ± 8
Interventricular septal thickness, mm 10 ± 2 10 ± 2
Posterior wall thickness, mm 10 ± 2 10 ± 2
LV end-diastolic diameter, mm 50 ± 8 48 ± 7
LV end-systolic diameter, mm 36 ± 10 34 ± 9
Fractional shortening, % 30 ± 10 30 ± 9
LV outflow diameter, mm 21 ± 1 20 ± 2*
Stroke volume, ml 60 ± 12 52 ± 15*
E/E’ 9±4 1 1±6
Aortic valve calcification, % 30 68*
Peak velocity across the aortic valve, m/s 1.27 ± 0.21 1.70 ± 0.41*
Mean pressure gradient across the aortic valve, mmHg 3.53 ± 1.17 6.20 ± 3.28*
Aortic valve area, cm
2 2.58 ± 0.39 1.62 ± 0.33*
AS: aortic stenosis; LV: left ventricular; E/E’: ratio of peak early diastolic transmitral flow velocity to peak early diastole mitral annular velocity. *P < 0.05 versus
non-AS.
Figure 1 Two-dimentioal and Doppler echocardiographic images from a patient without CKD or CAD. CKD: chronic kidney disease; CAD:
coronary artery disease.
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Page 4 of 9Figure 2 Two-dimentioal and Doppler echocardiographic images from a patient with both CKD and CAD. CKD: chronic kidney disease;
CAD: coronary artery disease.
Figure 3 Plots showing aortic valve area index in group 1 (absence of CKD and CAD, n = 16), group 2 (presence of either CKD or
CAD, n = 51), and group 3 (presence of both CKD and CAD, n = 53). CKD: chronic kidney disease; CAD: coronary artery disease.
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We quantified the AVA index by transthoracic echocar-
diography in consecutive patients receiving coronary
angiography and clarified that CKD, even pre-stage 5
CKD, was the most powerful determinant of AVA index
among a high risk population for coronary atherosclerosis.
Calcific aortic valve disease is frequent in the general
population and is associated with high cardiovascular risk
[1,2]. This valvular disease is a slowly progressive disorder
with a disease continuum that ranges from mild valve
thickening without obstruction of blood flow, termed aor-
tic sclerosis, to severe calcification with impaired leaflet
motion, or AS [21]. The pathologic mechanisms involved
in the disease include active processes that are similar to
those occurring in coronary atherosclerosis, such as the
impairment of endothelium, inflammation, and lipid infil-
tration [21-23]. Thus, calcific aortic valve disease has been
widely shown to correlate with the presence and severity
of CAD [3,24,25].
Despite the similarities in the histopathologic features
and clinical factors associated with calcific aortic valve
disease and coronary atherosclerosis, however, discrepan-
cies also exist. For example, although calcific changes can
be seen in the atherosclerotic plaques of coronary
arteries, calcification occurs earlier and is a more promi-
nent feature of calcific aortic valve disease, particularly in
the end stages of the disease process, and a large contri-
butor of disease progression is prominent calcification
with a gradual increase in leaflet thickness and outflow
obstruction [26]. The importance of tissue calcification in
the disease process is highlighted by the observation that
subsets of patients with altered mineral metabolism such
as CKD have a higher prevalence of calcific aortic valve
disease and more rapid disease progression [6-9]. How-
ever, most previous studies have demonstrated an asso-
ciation between end-stage renal disease and calcific
cardiovascular disease, especially in patients on dialysis
[6-9], and therefore, less is known about the impact of
early stage CKD on the prevalence and severity of calcific
aortic valve disease. The present study indicates that
patients with early stage CKD have an increased preva-
lence of AS in the populations at high risk for coronary
atherosclerosis. Notably, most of patients with CKD in
the present study were in stage 3, and mean eGFR in
patients with and without AS was 64 ± 23 and 53 ± 18
ml/min/1.73 m
2, respectively, suggesting that small dif-
ferences in renal function in early stages CKD can contri-
bute to the progression of calcific aortic valve disease in
patients at high risk for coronary atherosclerosis.
Although it would be difficult to address the underlying
mechanisms that are responsible for the progression of
calcific aortic valve disease in these earlier stages of CKD,
the present study suggests that latent alterations in multi-
ple factors such as inflammation, anemia, oxidative stress,
abnormal calcium/phosphate metabolism, and hemody-
namic overload may interdependently contribute to the
disease process, even when serum calcium/phosphate
levels are within normal ranges, and c-reactive protein
Figure 4 Plots showing peak velocity across the aortic valve in group 1 (absence of CKD and CAD, n = 16), group 2 (presence of
either CKD or CAD, n = 51), and group 3 (presence of both CKD and CAD, n = 53). CKD: chronic kidney disease; CAD: coronary artery
disease.
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meters of LV filling pressure are statistically similar
between patients with and without AS. Although the pre-
sent study did not focus on activation of proinflammatory
mechanisms as a causal mechanism for the progression
of calcific aortic valve disease, Aikawa et al demonstrated
that proinflammatory cathepsin S, a highly potent elas-
tase, contributes to arterial and valvular calcification in
mice with atherosclerosis and CKD assessed by in vivo
and ex vivo optical molecular imaging [27]. They used
molecular imaging of early calcification and elastolytic
activity to address new mechanisms underlying acceler-
ated calcification in patients with CKD and suggested
that calcification is a multifactorial process induced by
proinflammatory stimuli that promote accumulation of
elastolytic macrophages. Although the present study did
not focus on abnormalities in mineral metabolism as a
causal mechanism for the progression of calcific aortic
valve disease, previous clinical studies have demonstrated
that a decrease in 1,25-dihydroxyvitamin D and an
increase in parathyroid hormone (PTH) are the earliest
mineral metabolic events that take place in CKD, while
serum calcium and phosphate levels are altered later in
the course of CKD [28]. Adeney et al. demonstrated that
higher serum phosphate concentrations within the nor-
mal laboratory range were associated with a statistically
greater prevalence of coronary artery, descending thor-
acic aorta, and mitral valve calcification in a community-
based cohort of individuals with moderate CKD and no
clinically apparent cardiovascular disease [29]. A decline
in renal function leads to phosphate retention, elevated
PTH levels, and low 1,25-dihydroxy vitamin D levels;
however, serum phosphate levels are often maintained
within the normal laboratory range until relatively late in
the course of CKD [30-32]. Therefore, evaluation of the
levels of serum PTH and 1,25-dihydroxy vitamin D, early
markers for impaired mineral metabolism, is important
to clarify the underlying mechanisms that are responsible
for the progression of calcific aortic valve disease in early
stage CKD.
Several studies have documented an overlap in the clin-
ical factors traditionally associated with calcific valve dis-
ease and coronary atherosclerosis [33-38]. In the
prospective population-based Cardiovascular Health
Study, which included 5621 adults over the age of 65
years, clinical factors associated with calcific aortic valve
disease included age, gender, smoking, hypertension, and
hyperlipidemia [33]. However, CKD was not included as
a potential contributor to aortic valve calcification and
stenosis in these studies. In contrast, our study demon-
strated that conventional risk factors for cardiovascular
atherosclerosis were not independently related to the
progression of aortic valve disease, possibly because they
were well-controlled. Despite receiving adequate risk fac-
tor management, more than half of the patients devel-
oped CKD in the present study, and CKD, even pre-stage
5 CKD, has a more powerful impact on the presence and
severity of AS than other conventional risk factors for
atherosclerosis in patients at high risk for CAD. These
results indicate that patients with CKD should be
included as part of the highest risk group for the progres-
sion of calcific aortic valve disease. Aortic valve calcifica-
tion impairs the movement of aortic valve leaflets, which
affects cardiac function, and can only be alleviated
through costly and invasive procedures. Therefore, early
diagnosis of and interference with aortic valve calcifica-
tion could provide enormous clinical benefits.
Although 34% of patients were diagnosed with AS based
on AVA, the average value of their peak velocities and
mean pressure gradients across the aortic valve were only
1.70 ± 0.41 m/sec and 6.20 ± 3.28 mmHg, respectively.
Patients with AS in our study population were older, had
smaller body size, were more often women, and had smal-
ler LVOT diameter compared with those without AS,
which may partially be associated with low-flow and low-
gradient AS [39]. Nevertheless, the present study demon-
strated that presence of both with CKD and CAD had a
great impact on reduced AVA index and elevated peak
velocity across the aortic valve.
A potential limitation of the present study was the small
sample population, although we succeeded in testing our
primary hypothesis, which showed the impact of CKD on
the presence and the severity of AS in patients at high risk
for CAD. Three dimensional measurements of LVOT and
aortic valve area were not involved in this study. However,
Doppler-derived estimation of AVA using two-dimen-
sional transthoracic echocardiography is considered to
correlate well with simultaneous catheter-derived mea-
surements, and is widely used clinically [14-16]. Invasive
pressure measurements were not involved in the present
study; therefore, evaluation of AVA using Gorlin’s formula
was not possible. Also, direct measures of LV end-diastolic
pressure or pulmonary wedge pressure were not possible.
Accordingly, E/E’ was recruited as a marker of LV filling
pressure in the present study [17,18]. Finally, evaluation of
the rate of progression of aortic stenosis or the clinical
outcome was not included in our study. The long-term
effect of CKD on the progression of calcific aortic valve
disease warrants further investigation.
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